Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Share-based Compensation (2016 - 2025)

Wave Life Sciences' Share-based Compensation history spans 11 years, with the latest figure at $7.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 126.63% year-over-year to $7.4 million; the TTM value through Dec 2025 reached $25.0 million, up 90.04%, while the annual FY2025 figure was $25.0 million, 90.04% up from the prior year.
  • Share-based Compensation reached $7.4 million in Q4 2025 per WVE's latest filing, up from $6.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.4 million in Q4 2025 to a low of $2.3 million in Q3 2023.
  • Average Share-based Compensation over 5 years is $4.1 million, with a median of $3.5 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: skyrocketed 155.33% in 2022, then tumbled 65.34% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $3.7 million in 2021, then decreased by 21.98% to $2.9 million in 2022, then decreased by 19.09% to $2.4 million in 2023, then soared by 37.93% to $3.2 million in 2024, then soared by 126.63% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Share-based Compensation are $7.4 million (Q4 2025), $6.5 million (Q3 2025), and $6.2 million (Q2 2025).